Skyrizi (Risankizumab-rzaa) for Psoriasis

Overview
Skyrizi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis in cases where systemic therapy or phototherapy are appropriate. Skyrizi is also referred to by its drug name, risankizumab-rzaa.

Skyrizi is a biologic drug. Skyrizi is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Skyrizi is believed to work by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks. Skyrizi prevents the overproduction of IL-23 in the immune system.

How do I take it?
Prescribing information states that Skyrizi is administered as a subcutaneous injection every 12 weeks after initial loading doses.

Skyrizi comes in a prefilled, single-dose syringe.

Side effects
The FDA-approved label for Skyrizi lists common side effects including upper respiratory infections, headache, fatigue, injection site reactions, and ringworm.

Rare but serious side effects listed for Skyrizi can include increased risk for serious infections, including tuberculosis.

For more details about this treatment, visit:

Skyrizi — AbbVie
https://www.skyrizi.com